Current Report Filing (8-k)
11 December 2018 - 10:14PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 11, 2018
Nexeon
Medsystems Inc
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-55655
|
|
81-0756622
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
1910
Pacific Avenue, Suite 20000
Dallas,
Texas 75201
(Address
of principal executive offices) (zip code)
844-919-9990
|
(Registrant’s
telephone number, including area code)
|
|
Not
applicable
|
(Former
name or former address, if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
Nexeon
Medsystems Inc (the “Company”) has made available an updated presentation about its business, a copy of which is filed
as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”) and is hereby incorporated by reference.
The
information contained in the presentation is summary information that should be considered in the context of the Company’s
filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise
from time to time. The presentation speaks as of the date of this Report. While the Company may elect to update the presentation
in the future to reflect events and circumstances occurring or existing after the date of this Report, the Company specifically
disclaims any obligation to do so.
The
presentation contains forward-looking statements, and as a result, investors should not place undue reliance on these forward-looking
statements.
The
information set forth in this Report, including without limitation the presentation, is not deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific
reference in such a filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
The
exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
NEXEON
MEDSYSTEMS INC
|
|
|
Dated:
December 11, 2018
|
/s/
William Rosellini
|
|
William
Rosellini
|
|
Chairman
and Chief Executive Officer
|
Nexeon Medsystems (CE) (USOTC:NXNN)
Historical Stock Chart
From Feb 2025 to Mar 2025
Nexeon Medsystems (CE) (USOTC:NXNN)
Historical Stock Chart
From Mar 2024 to Mar 2025
Real-Time news about Nexeon Medsystems Inc (CE) (OTCMarkets): 0 recent articles
More Nexeon Medsystems Inc News Articles